Skip to main content

Novel Rx

Dr. John Cush
@RheumNow
T-Cell Engagers in Autoimmunity: CRS From 12% to 67% Across Six Reports Six ACR 2026 reports put BCMA, CD19, CD20 and gamma-delta engagers side by side in autoimmune disease. The efficacy signal is consistent. The safety signal depends almost entirely on how the molecule was https://t.co/PHm1fF3Tg4
Dr. John Cush
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/EkudaG7YiY
Dr. John Cush
@RheumNow
Efgartigimod: A New Mechanism for Myositis? Abstracts come and go, but new trials and new mechanisms stay with us for the long haul. One of the more interesting new mechanisms is the FcRn drugs, and at ACR Convergence 2026 we got to see positive results from the Phase 3 ALKIVIA https://t.co/cCgItPQSPS
Dr. John Cush
@RheumNow
Why Did the Last Drug Fail? When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes https://t.co/r5mQjI79iQ
Dr. John Cush
@RheumNow
Making the Case for Early Biologics in Lupus A new diagnosis of SLE can be overwhelming for patients. The decision to initiate biologic versus non-biologic therapy early in the disease course may have far-reaching implications for disease control, glucocorticoid exposure, and https://t.co/CmTeHTwzZw
Dr. John Cush
@RheumNow
New Treatment for Fibromyalgia? Will It Help or Harm? For years, the pharmacologic treatment landscape for fibromyalgia has remained relatively unchanged, with limited therapeutic options despite a substantial disease burden. This condition is characterized by chronic https://t.co/nn9wu7xibY
Dr. John Cush
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/30MGwIRUgO
Dr. John Cush
@RheumNow
Are GLP-1s Doing More Than Shrinking Waistlines in PsA? In abstract #0373, Pankti Mehta and colleagues examined patients from a longitudinal PsA cohort who initiated GLP-1 receptor agonist or dual GIP/GLP-1 therapy and compared them with matched controls. Baseline body mass https://t.co/FGCszLnS4N
Dr. John Cush
@RheumNow
Beyond Joint Inflammation: Does Early RA Control Prevent Chronic Pain and Fatigue? Could the therapeutic window of opportunity in rheumatoid arthritis extend beyond preventing structural damage to preventing chronic pain, fatigue, and neuroimmune complications? This is the https://t.co/WVSjwIHOAM
anita
@docdhanrajani
@RheumNow 🎉 Celebrated 50 years of #PediatricRheumatology at #ACR2026! Meet the Masters: 3 pioneers reflected on the evolution of our field—from early genetics and DMARDs to biologics—and envisioned the future of precision medicine, novel therapies, and mentorship. What a treat
Daric Mueller, PA-C
@rheumPAC
(1/2)#ACRBest Dazodalibep (DAZ) for systemically active SjD Ph3 top line results! LB22 648 pts IV DAZ 1500mg Q4W or 3000mg Q12W vs placebo Signf improved ESSDAI in both DAZ arms @ 48W. ESDAI differences vs placebo -1.8 for 1500mg Q4W, -1.4 for 3000mg Q12W @RheumNow #ACR26
Akhil Sood MD, MS
@AkhilSoodMD
Abstract 2969: surveyed pts w/ lupus about clinical trial awareness - 87% patients reported informed about their dx w/ physicians as main source (94%) - cliniical trial knowledge lower (44%) - 84% expressed interest in trials - travel most common barrier @RheumNow #ACR26
Sadhak Sengupta
@sadhaksengupta
@Aclockworkolive @drdavidliew @NEJM @RheumNow Both rap-cel and zola-cel targets to keep the infusion material enriched in CCR7+CD27+ naive state, for which the ex vivo part of the expansion has to be stopped before the cells start differentiating. Longer the ex vivo culture, higher the percentage of differentiation.

TRBV9+ a novel treatment approach for AxSpA?

Peter Nash

HLA-B27 is the strongest genetic risk factor for AxSpA positive in 90% of rAxSpA and 30-40% of PsA patients. B27 is an MHC class1 molecule which presents peptide to CD8 T cells. Current therapies treat inflammation but do not eliminate the cellular drivers of disease and only 40-60% of AxSpA

×